According to a re-Tweet by The Street's Adam Feuerstein, Intercept said at today's JMP conference that it's highly unlikely it will be able to get the FLINT data in July after hearing last night from the National Institute of Diabetes and Digestive and Kidney Diseases. Shares of Intercept are down 4% to $262.77 in early trading.
I would love to see this add a few more today!!!
cant happen soon enough crooks
RBC Capital Initiates Coverage on Intercept at Outperform, Announces $425.00 PT
Last update: 30/06/2014 4:04:45 pm
RBC Capital initiates coverage on Intercept (NASDAQ: ICPT) with a Outperform rating and a $425.00 price target, according to Bloomberg.
GS getting sued by 2 women former employees good ole boys meetings held at strip clubs.
I have no position.I pray for a super short squeeze he prolly covered some today...